Morphine Pharmacology

Quick Answer

Morphine is the prototypical natural opioid analgesic derived from the phenanthrene alkaloid class, acting as a full agonist at mu (μ), kappa (κ), and delta (δ) opioid receptors with primary clinical effects mediated through mu-receptor activation. Its pharmacokinetics are characterised by variable oral bioavailability (20-40%) due to extensive first-pass hepatic metabolism, a volume of distribution of 3-4 L/kg, and hepatic glucuronidation via UGT2B7 to two primary metabolites: morphine-3-glucuronide (M3G, ~55%, inactive/neuroexcitatory) and morphine-6-glucuronide (M6G, ~10%, potent analgesic activity 20-45× morphine). The clinical significance of M6G accumulation in renal impairment cannot be overstated—patients with reduced creatinine clearance are at high risk of prolonged sedation, respiratory depression, and neurotoxicity. Morphine produces dose-dependent analgesia, sedation, euphoria, respiratory depression (via pre-Bötzinger complex), nausea (chemoreceptor trigger zone), miosis, and reduced gastrointestinal motility. Cardiovascular effects include histamine release causing vasodilation and hypotension, with minimal direct cardiac depression. Routes of administration include oral, intravenous, intramuscular, subcutaneous, epidural, and intrathecal, each with specific pharmacokinetic considerations. [1-8]

Chemical Structure and Classification

Phenanthrene Alkaloid Structure

Morphine (chemical name: (5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol) is a naturally occurring phenanthrene alkaloid derived from the opium poppy (Papaver somniferum). The molecular formula is C17H19NO3 with a molecular weight of 285.34 Da. The phenanthrene nucleus consists of three fused rings (benzene-cyclohexene-cyclohexene) forming a rigid T-shaped structure with five chiral centres, giving morphine its characteristic three-dimensional conformation essential for opioid receptor binding. [9-11]

The structure contains several pharmacologically important functional groups:

• 3-phenolic hydroxyl group: Essential for mu-receptor binding and analgesic activity
• 6-hydroxyl group: Site of glucuronidation to M6G; modification affects potency
• 17-nitrogen (N-methyl group): Required for receptor interaction; demethylation produces normorphine
• 4,5-epoxy bridge: Maintains structural rigidity necessary for receptor fit
• 7,8-double bond: Part of the phenanthrene ring system

The phenolic 3-OH group is particularly important—methylation produces codeine (reduced potency, prodrug requiring CYP2D6 conversion to morphine), while acetylation of both 3-OH and 6-OH groups produces diacetylmorphine (heroin), which has greater lipophilicity and faster CNS penetration. [12-15]

Natural Opioid Classification

Morphine is classified as a natural opioid, distinguished from:

• Semi-synthetic opioids: Derived from morphine (e.g., hydromorphone, oxycodone, heroin)
• Synthetic opioids: Entirely synthesised (e.g., fentanyl, methadone, tramadol)

As a full agonist, morphine produces maximal receptor activation at sufficiently high doses, contrasting with:

• Partial agonists: Buprenorphine (ceiling effect for analgesia and respiratory depression)
• Mixed agonist-antagonists: Pentazocine, nalbuphine (mu antagonist/kappa agonist)
• Pure antagonists: Naloxone, naltrexone

Morphine remains the "gold standard" opioid analgesic against which all others are compared, with a relative potency of 1.0 by definition. Understanding its pharmacology is fundamental to ANZCA Primary examination success. [16-18]

Mechanism of Action

Opioid Receptor Subtypes

Morphine exerts its pharmacological effects through interaction with three classical opioid receptor subtypes, all members of the G protein-coupled receptor (GPCR) superfamily:

Morphine has highest affinity for mu receptors (Ki ≈ 1-2 nM), with lower affinity for delta (Ki ≈ 90 nM) and kappa (Ki ≈ 200 nM) receptors. The clinical effects of morphine are predominantly mu-receptor mediated. A fourth receptor (nociceptin/orphanin FQ receptor, NOP) exists but morphine has negligible activity at this site. [19-22]

G-Protein Signalling Cascade

Opioid receptors are coupled to inhibitory G proteins (Gi/Go). Upon morphine binding, the following intracellular cascade occurs:

1. G-protein activation: Morphine binding induces conformational change, promoting GDP→GTP exchange on the Gα subunit
2. Subunit dissociation: The Gα-GTP and Gβγ subunits dissociate and interact with downstream effectors
3. Adenylyl cyclase inhibition: Gαi inhibits adenylyl cyclase, reducing intracellular cyclic AMP (cAMP) production
4. Ion channel modulation:
   • Gβγ activates G protein-coupled inwardly rectifying potassium channels (GIRK/Kir3), causing K+ efflux and membrane hyperpolarisation
   • Gβγ inhibits voltage-gated calcium channels (N-type, P/Q-type), reducing Ca2+ influx and neurotransmitter release
5. Presynaptic inhibition: Reduced calcium influx in primary afferent terminals decreases substance P and glutamate release
6. Postsynaptic hyperpolarisation: Increased potassium conductance hyperpolarises postsynaptic neurons, reducing excitability

The net effect is reduced nociceptive transmission at both spinal (dorsal horn) and supraspinal (periaqueductal grey, rostral ventromedial medulla) levels. [23-26]

Sites of Analgesic Action

Supraspinal mechanisms:

• Periaqueductal grey (PAG): Activation disinhibits descending inhibitory pathways
• Rostral ventromedial medulla (RVM): Modulates descending serotonergic and noradrenergic inhibition
• Thalamus: Reduces nociceptive relay to cortex
• Limbic system: Modifies affective component of pain perception

Spinal mechanisms:

• Dorsal horn (laminae I, II): Direct inhibition of nociceptive transmission
• Presynaptic inhibition: Reduced substance P and glutamate release from C-fibre terminals
• Postsynaptic inhibition: Hyperpolarisation of projection neurons

The synergistic interaction between spinal and supraspinal sites explains the enhanced analgesia seen with combined systemic and neuraxial opioid administration. [27-30]

Pharmacokinetics

Absorption

Oral absorption:

• Morphine is well absorbed from the gastrointestinal tract (absorption >90%)
• Extensive first-pass hepatic metabolism reduces oral bioavailability to 20-40% (mean ~30%)
• Peak plasma concentration (Tmax) occurs at 30-60 minutes for immediate-release formulations
• Sustained-release preparations (MS Contin, Kapanol) have Tmax of 2-4 hours
• Food has minimal effect on total absorption but may delay Tmax

Parenteral absorption:

• Intramuscular: Bioavailability ~100%, onset 15-30 minutes, peak effect 30-60 minutes
• Subcutaneous: Similar to IM, onset 15-30 minutes, reliable absorption even in oedematous patients
• Intravenous: Immediate bioavailability, onset 5-10 minutes (time to peak effect-site concentration)

Neuraxial absorption:

• Epidural: Onset 15-30 minutes, duration 12-24 hours, systemic absorption occurs over hours
• Intrathecal: Onset 15-45 minutes, duration 12-24 hours, extremely small doses (0.1-0.5 mg) effective

The hydrophilic nature of morphine (octanol:water partition coefficient = 1.4, compared to fentanyl = 816) results in slower CNS penetration but prolonged neuraxial duration due to limited rostral spread and delayed clearance from CSF. [31-35]

Distribution

• Volume of distribution (Vd): 3-4 L/kg (200-300 L in 70 kg adult), indicating extensive tissue distribution
• Plasma protein binding: 30-35%, primarily to albumin; relatively low compared to fentanyl (84%) and sufentanil (93%)
• Blood-brain barrier penetration: Relatively slow due to low lipophilicity and ionisation at physiological pH
• pKa: 7.9, meaning ~23% unionised at pH 7.4 (compared to fentanyl pKa 8.4, ~10% unionised)
• Effect-site equilibration (t1/2keo): 2-4 minutes (slower than fentanyl 4-6 minutes due to hydrophilicity)

Despite low lipophilicity, morphine's small molecular size and low protein binding allow adequate CNS penetration, though onset is slower than lipophilic opioids. The relatively large Vd reflects distribution into muscle, kidney, liver, lung, spleen, and to a lesser extent adipose tissue. [36-39]

Metabolism

Morphine undergoes extensive hepatic metabolism, primarily through Phase II conjugation reactions:

Primary metabolic pathway - Glucuronidation (UGT2B7):

Key enzyme: UDP-glucuronosyltransferase 2B7 (UGT2B7)

• Primary enzyme responsible for morphine glucuronidation
• Located in hepatocytes and, to a lesser extent, kidney and intestine
• Genetic polymorphisms affect M6G:M3G ratio but clinical significance variable
• Not significantly induced or inhibited by common drugs (unlike CYP450 enzymes)

The M6G:M3G ratio is clinically important. Higher M6G production is associated with greater analgesia but also increased risk of toxicity. In renal impairment, M6G half-life increases from 3-4 hours to 50+ hours, leading to dangerous accumulation. [40-45]

Elimination

• Elimination half-life (t1/2β): 2-4 hours in adults with normal renal and hepatic function
• Total body clearance: 15-30 mL/kg/min (approximately 1-2 L/min in 70 kg adult)
• Hepatic extraction ratio: 0.6-0.7 (intermediate), meaning clearance is dependent on both hepatic blood flow and enzyme capacity

Renal excretion:

• 90% of morphine dose excreted as glucuronide metabolites in urine
• <10% excreted as unchanged morphine
• M6G: Normal half-life 3-4 hours; in ESRF increases to 50-150 hours
• M3G: Normal half-life 3-5 hours; in ESRF increases to 50-150 hours

Hepatic impairment effects:

• Reduced first-pass metabolism increases oral bioavailability (may reach 80-100% in severe cirrhosis)
• Reduced glucuronidation capacity prolongs elimination half-life
• Dose reduction of 50-75% recommended in severe hepatic impairment

Renal impairment effects (CRITICAL for exam):

M6G is poorly dialysed (molecular weight 461 Da, but high water solubility limits membrane transfer). Patients on haemodialysis remain at risk of toxicity despite regular dialysis sessions. [46-52]

Pharmacodynamics

Analgesic Effect and Dose-Response

Morphine produces dose-dependent analgesia following a sigmoid Emax model. Key pharmacodynamic parameters:

• EC50 (effective concentration for 50% maximal effect): 15-30 ng/mL plasma concentration
• Minimum effective analgesic concentration (MEAC): Variable between patients (10-40 ng/mL), influenced by pain type, prior opioid exposure, and genetic factors
• Therapeutic range: Generally 10-80 ng/mL; toxicity more likely above 100 ng/mL
• No true ceiling effect: Unlike partial agonists, dose escalation continues to increase analgesia (and adverse effects)

The steep dose-response relationship means small dose changes produce significant effect changes, necessitating careful titration. Individual variation in morphine response spans a 10-fold range, explained by:

1. Pharmacokinetic variability: UGT2B7 polymorphisms, hepatic function, renal function
2. Pharmacodynamic variability: OPRM1 gene polymorphisms (A118G variant affects receptor expression), receptor density, prior opioid exposure
3. Pain type: Neuropathic pain less responsive than nociceptive pain

The time to peak effect after IV administration is 15-30 minutes (slower than fentanyl 3-5 minutes) due to morphine's lower lipophilicity and slower blood-brain equilibration. [53-57]

Receptor Selectivity and Effects

Morphine's selectivity ratio is approximately:

• Mu : Kappa : Delta = 1 : 0.02 : 0.01

This high mu-selectivity accounts for the characteristic morphine effect profile. Kappa activation contributes to spinal analgesia and sedation but also dysphoria at high doses. Delta receptor activation may modulate mood and anxiety components of pain. [58-60]

Central Nervous System Effects

Analgesia

Morphine provides effective analgesia for moderate to severe pain through:

• Raising pain threshold (reduced perception of noxious stimuli)
• Modifying affective response to pain (reduced suffering/distress)
• Drowsiness and sedation contributing to overall comfort

Most effective for: Visceral pain, somatic nociceptive pain, cancer pain Less effective for: Neuropathic pain, procedural pain (requires higher doses)

Sedation and Consciousness

• Dose-dependent sedation from drowsiness to obtundation
• Reduced anxiety and apprehension
• Disruption of normal sleep architecture (decreased REM sleep, increased light non-REM sleep)
• At high doses: Unconsciousness (but not true general anaesthesia—awareness and recall possible)

Euphoria and Dysphoria

• Euphoria ("well-being") common in pain-free subjects; less pronounced when treating pain
• Dysphoria may occur, particularly with kappa-receptor activation or in opioid-naïve patients
• Limbic system (nucleus accumbens) dopamine release underlies rewarding properties

Miosis

• Pupillary constriction (pinpoint pupils) is pathognomonic of opioid effect
• Mediated by mu-receptor stimulation of Edinger-Westphal nucleus
• No tolerance develops to miosis—useful clinical sign even in chronic opioid users
• Exception: Meperidine causes mydriasis due to anticholinergic properties

Nausea and Vomiting

• Incidence: 20-40% of patients receiving parenteral morphine
• Mechanism: Direct stimulation of chemoreceptor trigger zone (CTZ) in area postrema
• Vestibular component: Movement exacerbates opioid-induced nausea
• Tolerance develops within 3-5 days of regular use
• Prevention/treatment: Ondansetron, droperidol, metoclopramide, cyclizine

Respiratory Depression

This is the most serious adverse effect and primary cause of opioid-related death.

Mechanism:

• Direct depression of brainstem respiratory centres, particularly the pre-Bötzinger complex
• Reduced sensitivity to CO2 (elevated apnoeic threshold)
• Reduced sensitivity to hypoxia
• Depression of pontine respiratory group affecting respiratory rhythm

Characteristics:

• Reduced respiratory rate (bradypnoea) is earliest sign
• Reduced tidal volume (later effect)
• Irregular breathing pattern
• Apnoea at high doses

Risk factors for clinically significant respiratory depression:

• Opioid-naïve patients
• Concurrent sedatives (benzodiazepines, alcohol)
• Sleep apnoea
• Respiratory disease (COPD, asthma)
• Renal impairment (M6G accumulation)
• Elderly patients
• High doses, rapid administration

Reversal: Naloxone 0.1-0.4 mg IV, titrated to respiratory rate >12/min while maintaining analgesia if possible. Duration of naloxone (30-90 minutes) may be shorter than morphine, requiring repeat dosing or infusion. [61-66]

Cardiovascular Effects

Histamine Release

Morphine causes dose-dependent histamine release from mast cells through non-immunological (direct) mechanisms:

• Vasodilation: Arteriolar and venous dilation causing hypotension
• Flushing: Cutaneous vasodilation, particularly face, neck, upper chest
• Pruritus: Histamine-mediated itching (though central mechanisms also contribute)
• Bronchospasm: Rare but possible in susceptible individuals (asthmatics)

The degree of histamine release is:

• Morphine > Meperidine > Fentanyl > Sufentanil > Remifentanil (negligible)

Slow IV administration (1-2 mg/min) reduces histamine release compared to rapid bolus.

Hypotension

Mechanisms:

1. Histamine-mediated vasodilation (peripheral resistance ↓)
2. Reduced sympathetic tone (central effect)
3. Vagal stimulation causing bradycardia
4. Venodilation reducing preload

Magnitude: 10-20% reduction in MAP is common; may be profound in:

• Hypovolaemic patients
• Patients on vasodilators or ACE inhibitors
• Patients with autonomic dysfunction

Prevention: Adequate volume status, slow administration, avoid in hypovolaemia

Bradycardia

• Vagally mediated reduction in heart rate
• Usually mild (5-10 bpm reduction)
• Significant bradycardia rare unless combined with other vagotonic drugs
• Treatment: Atropine 0.4-0.6 mg IV if symptomatic

Myocardial Effects

• Minimal direct negative inotropic effect
• No significant arrhythmogenic potential
• Relatively cardio-stable compared to propofol or thiopental
• May be beneficial in acute coronary syndromes (reduced preload, reduced sympathetic drive) [67-71]

Respiratory Effects

Respiratory Centre Depression

Morphine produces dose-dependent depression of respiratory drive through action on brainstem respiratory centres:

Pre-Bötzinger complex:

• Primary respiratory rhythm generator
• Contains mu-opioid receptors on inspiratory neurons
• Opioid binding reduces neuronal firing rate and respiratory rhythm

Nucleus tractus solitarius (NTS):

• Integrates peripheral chemoreceptor input
• Opioids reduce response to hypoxia and hypercapnia

Parabrachial nucleus:

• Modulates respiratory pattern
• Opioids disrupt normal breathing variability

Quantitative effects:

• Minute ventilation reduced 30-50% at analgesic doses
• CO2 response curve shifted right and slope reduced
• Hypoxic ventilatory response blunted (particularly dangerous)
• Apnoeic threshold elevated by 5-7 mmHg

Cough Suppression (Antitussive Effect)

• Morphine effectively suppresses cough reflex
• Mediated by action on cough centre in medulla
• Lower doses required than for analgesia
• Codeine commonly used as antitussive (but efficacy questioned in recent trials)
• Useful in palliative care for intractable cough

Bronchospasm

• Rare complication, primarily histamine-mediated
• More common in asthmatics or those with reactive airways
• Morphine is not absolutely contraindicated in asthma but caution warranted
• Fentanyl and its analogues are preferred in patients with significant bronchospastic disease [72-76]

Gastrointestinal Effects

Constipation

Morphine causes constipation through multiple mechanisms:

1. Reduced propulsive peristalsis: Mu-receptor activation in myenteric plexus reduces coordinated contractions
2. Increased segmental contractions: Non-propulsive contractions increase
3. Increased sphincter tone: Pyloric, ileocaecal, and anal sphincter tone increases
4. Reduced secretions: Intestinal fluid secretion decreases
5. Central effects: Reduced responsiveness to defaecation reflex

Clinical characteristics:

• Occurs in 40-90% of patients on chronic opioid therapy
• No tolerance develops—requires ongoing laxative therapy
• May be severe enough to cause faecal impaction, bowel obstruction
• Opioid-induced constipation (OIC) is a recognised clinical entity

Management:

• Prophylactic laxatives in all patients on regular opioids
• First-line: Stimulant laxative (senna, bisacodyl) + osmotic (macrogol, lactulose)
• Refractory: Peripherally acting mu-opioid receptor antagonists (PAMORAs):
  • Naloxegol (oral)
  • Methylnaltrexone (subcutaneous)

Delayed Gastric Emptying

• Morphine prolongs gastric emptying time by 40-100%
• Relevant for patients requiring rapid sequence induction (full stomach risk)
• May reduce absorption of oral medications
• Contributes to nausea and early satiety

Biliary Effects

• Morphine causes contraction of sphincter of Oddi
• May increase biliary pressure and precipitate biliary colic
• Historically considered contraindicated in biliary colic (though evidence weak)
• If required, may co-administer glyceryl trinitrate or glucagon to relax sphincter [77-81]

Routes of Administration

Oral Administration

Immediate-release preparations:

• Morphine sulfate oral solution: 2 mg/mL, 20 mg/mL concentrations
• Immediate-release tablets: 10 mg, 20 mg, 30 mg
• Onset: 20-40 minutes; Peak: 60-90 minutes; Duration: 3-4 hours
• Usual dose: 10-30 mg every 4 hours

Sustained-release preparations:

• MS Contin (morphine sulfate controlled-release): 5, 10, 15, 30, 60, 100, 200 mg
• Kapanol (morphine sulfate extended-release capsules): 10, 20, 50, 100 mg
• Onset: 1-2 hours; Peak: 2-4 hours; Duration: 8-12 hours (MS Contin) or 12-24 hours (Kapanol)
• Must be swallowed whole—crushing destroys controlled-release mechanism, causing dose-dumping

Intravenous Administration

• Most reliable route for acute pain management
• Standard bolus: 0.05-0.1 mg/kg (2.5-10 mg in adults)
• Onset: 5-10 minutes; Peak effect: 15-30 minutes; Duration: 3-4 hours
• PCA settings typically: 1 mg bolus, 5-minute lockout, ± background infusion
• Important: Titrate slowly in opioid-naïve patients; observe for respiratory depression

Intramuscular/Subcutaneous Administration

• Bioavailability: ~100% (bypasses first-pass metabolism)
• IM onset: 15-30 minutes; Peak: 30-60 minutes; Duration: 3-5 hours
• SC onset: 15-30 minutes; Peak: 60-90 minutes; Duration: 4-6 hours
• SC route increasingly preferred (less painful, equivalent absorption)
• Common in palliative care: Continuous subcutaneous infusion (CSCI) via syringe driver

Epidural Administration

• Dose: 2-5 mg single shot; 0.1-0.5 mg/hour infusion (often combined with local anaesthetic)
• Onset: 15-30 minutes; Duration: 12-24 hours
• Provides excellent analgesia with lower systemic doses
• Hydrophilic nature means slow rostral spread—watch for delayed respiratory depression (6-12 hours)
• Side effects: Pruritus (30-60%), nausea (30-40%), urinary retention (15-30%)

Intrathecal Administration

• Dose: 0.1-0.5 mg (100-500 mcg)—approximately 1/10th epidural dose
• Onset: 15-45 minutes; Duration: 12-24 hours
• Extremely effective analgesia with minimal systemic absorption
• Risk of delayed respiratory depression (peak 6-12 hours post-administration)
• Requires monitoring for 24 hours post-administration per ANZCA guidelines
• Used for: Major surgery, cancer pain (intrathecal pump), labour analgesia [82-87]

Drug Interactions

Pharmacodynamic Interactions

Pharmacokinetic Interactions

Note: Morphine metabolism (glucuronidation) is relatively resistant to CYP450 interactions, unlike methadone or fentanyl. [88-92]

Special Populations

Renal Impairment

This is the most critical special population consideration for morphine.

M6G is an active metabolite with analgesic potency 2-4× morphine. It is renally excreted with a half-life of 3-4 hours in normal renal function, increasing to 50-150 hours in end-stage renal failure.

Clinical consequences of M6G accumulation:

• Prolonged and profound sedation
• Respiratory depression (may occur 12-72 hours after "last" dose)
• Myoclonus, hyperalgesia (paradoxically, possibly due to M3G)
• Nausea and vomiting

Recommendations by renal function:

Morphine is poorly dialysed due to its large volume of distribution, and M6G clearance by haemodialysis is also limited. [93-96]

Hepatic Impairment

• Reduced first-pass metabolism increases oral bioavailability (from 30% to potentially 80-100%)
• Reduced glucuronidation capacity prolongs elimination half-life
• Reduced albumin may modestly increase free fraction

Recommendations:

• Mild impairment (Child-Pugh A): Standard doses with monitoring
• Moderate impairment (Child-Pugh B): Reduce oral dose 50%, extend interval
• Severe impairment (Child-Pugh C): Reduce dose 75%, use IV with titration, monitor closely

Elderly Patients

• Reduced renal function (even with "normal" creatinine) increases M6G accumulation risk
• Reduced hepatic blood flow and enzyme activity
• Increased CNS sensitivity (pharmacodynamic change)
• Higher prevalence of polypharmacy and drug interactions

Recommendations:

• Reduce initial dose by 25-50%
• "Start low, go slow"
• Longer dosing intervals (every 6 hours rather than every 4 hours)
• Monitor closely for sedation and respiratory depression

Pregnancy and Lactation

Pregnancy:

• Morphine crosses placenta freely
• Not teratogenic at therapeutic doses
• Neonatal respiratory depression if administered close to delivery
• Neonatal abstinence syndrome with chronic maternal use

Lactation:

• Morphine excreted in breast milk (M:P ratio 2.5)
• Single doses: Generally safe; observe infant for sedation
• Chronic use: Avoid or monitor infant closely; consider alternative [97-100]

Comparison with Other Opioids

When to prefer alternatives to morphine:

• Renal impairment: Fentanyl, hydromorphone, buprenorphine
• Histamine concerns: Fentanyl, hydromorphone
• Rapid onset required: Fentanyl
• Chronic therapy: Consider oxycodone, buprenorphine for stable kinetics [101-104]

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Considerations

Culturally safe pain management for Aboriginal and Torres Strait Islander peoples requires understanding of several important factors. Higher rates of chronic disease, including diabetes, cardiovascular disease, and chronic kidney disease in Indigenous Australians, significantly affect morphine pharmacokinetics—particularly the critical issue of M6G accumulation in renal impairment. Chronic kidney disease prevalence is 3-4 times higher in Indigenous Australians compared to non-Indigenous populations, making morphine a higher-risk analgesic choice.

Pain expression varies across cultures, and assessment tools should be culturally validated. Indigenous patients may describe pain differently, using terms related to spirit, country, or community rather than Western biomedical concepts. Family (mob) involvement in healthcare decisions is culturally appropriate and should be facilitated. Aboriginal Health Workers and Aboriginal Hospital Liaison Officers can provide invaluable assistance in pain assessment and medication counselling.

Remote and rural communities face significant challenges accessing healthcare, including limited pharmacy services, delayed presentations, and reduced access to specialist pain management. In remote settings, immediate-release oral morphine is more readily available than sustained-release formulations. Subcutaneous infusion pumps (syringe drivers) may be used for palliative care but require trained personnel.

Traditional medicine practices should be respectfully acknowledged. While direct interactions between morphine and bush medicines are unknown, a non-judgmental approach that integrates traditional and Western medicine improves patient engagement and outcomes.

Māori Health Considerations (Aotearoa New Zealand)

For Māori patients, whānau (family) involvement reflects the collective nature of Māori culture and should be supported throughout pain management. The concepts of hauora (holistic health encompassing taha tinana/physical, taha hinengaro/mental, taha whānau/family, taha wairua/spiritual dimensions) should inform pain assessment—addressing only physical pain may be insufficient if spiritual or family dimensions are neglected.

Māori experience significant health inequities, including higher rates of chronic disease and reduced access to specialist services. Culturally safe practice includes acknowledging tikanga (customs), demonstrating manaakitanga (hospitality/care), and recognising the mana (prestige/authority) of the patient in their own healthcare. [105-108]

ANZCA Primary Exam Focus

Common MCQ Patterns

1. Metabolism and metabolites: Questions frequently test knowledge of M3G and M6G formation via UGT2B7, relative activities of metabolites, and accumulation in renal failure

2. Renal impairment: High-yield topic—expect questions on M6G accumulation, clinical consequences, and appropriate opioid alternatives

3. Mechanism of action: G-protein signalling (Gi/Go), adenylyl cyclase inhibition, GIRK channel activation, calcium channel inhibition

4. Pharmacokinetic parameters: Oral bioavailability (30%), Vd (3-4 L/kg), protein binding (30-35%), elimination half-life (2-4 hours)

5. Comparative pharmacology: Morphine vs. fentanyl (lipophilicity, active metabolites, histamine release, renal safety)

6. Respiratory depression: Mechanism (pre-Bötzinger complex), CO2 response curve changes, risk factors

Viva Question Themes

• Draw and explain the opioid receptor signalling cascade
• Compare morphine and fentanyl pharmacokinetics—which is safer in renal failure?
• A patient on chronic morphine develops myoclonus—explain the mechanism
• Describe the factors affecting M6G formation and clearance
• How would you manage postoperative analgesia in a patient with eGFR 20?

Calculation Questions

Example 1: Oral to IV conversion A patient receives morphine 60 mg PO every 4 hours. What is the equivalent IV dose?

• Oral bioavailability ~30%, so IV:PO ratio is approximately 1:3
• 60 mg PO = 20 mg IV every 4 hours

Example 2: Intrathecal dose calculation The typical epidural:intrathecal ratio for morphine is 10:1. If an epidural dose is 3 mg, what is the equivalent intrathecal dose?

• 3 mg ÷ 10 = 0.3 mg (300 mcg) intrathecally

Example 3: PCA prescription Calculate an appropriate morphine PCA prescription for a 70 kg opioid-naïve patient post-laparotomy:

• Bolus: 1 mg (range 0.5-2 mg)
• Lockout: 5-8 minutes
• Background infusion: Generally avoided in opioid-naïve patients
• 4-hour maximum: 20-30 mg [109-112]

Assessment Content

SAQ Practice Question (20 marks)

Question: A 72-year-old woman (65 kg) with chronic kidney disease (eGFR 22 mL/min/1.73m²) presents for elective total hip replacement. She has well-controlled hypertension on amlodipine and type 2 diabetes. She has no previous opioid exposure.

(a) Discuss the pharmacokinetic considerations for morphine in this patient. (8 marks)

(b) What alternative opioids would be more appropriate, and why? (6 marks)

(c) If morphine is used despite the renal impairment, outline a monitoring and dosing strategy to minimise risk. (6 marks)

---

Model Answer:

(a) Pharmacokinetic considerations (8 marks)

Morphine metabolism and metabolites (3 marks):

• Morphine undergoes hepatic glucuronidation via UGT2B7 to M3G (~55%) and M6G (~10%)
• M6G is a potent mu-opioid agonist with 20-45× receptor affinity of morphine and approximately 2× clinical analgesic potency
• M3G is inactive but may be neuroexcitatory, potentially causing myoclonus and hyperalgesia

Renal elimination and accumulation (3 marks):

• Both glucuronide metabolites are renally excreted
• With eGFR 22 mL/min, M6G half-life increases from 3-4 hours to approximately 50+ hours
• Progressive accumulation leads to:
  • Delayed onset of sedation and respiratory depression (may occur 12-72 hours post-dose)
  • Prolonged duration of effect
  • Increased risk of serious toxicity

Patient-specific factors (2 marks):

• Elderly: Increased CNS sensitivity to opioids (pharmacodynamic factor)
• Diabetes: May have impaired renal function beyond GFR estimate; neuropathy may affect pain perception
• Hypertension medication: Amlodipine may enhance morphine-induced hypotension
• Opioid-naïve: No tolerance—full effect from initial doses

(b) Alternative opioids (6 marks)

(c) Monitoring and dosing strategy if morphine used (6 marks)

Dosing modifications (3 marks):

• Reduce dose by 75%: Use 25% of standard dose
• Extend dosing interval: Every 6-8 hours rather than every 4 hours
• Use PRN dosing only (not regular/scheduled) for acute pain
• Titrate slowly with observation between doses
• Consider oral route (better control than intermittent IV) once tolerating oral intake

Monitoring requirements (3 marks):

• Continuous pulse oximetry for at least 24-48 hours
• Regular sedation scoring (every 1-2 hours initially)
• Respiratory rate monitoring (target >10/min)
• Pain assessment using validated tool
• Daily review of renal function (creatinine may change post-surgery)
• Watch for late toxicity: Drowsiness developing on days 2-3 suggests M6G accumulation
• Have naloxone readily available; consider naloxone infusion if toxicity develops

Total: 20 marks

---

Viva Scenario (20 marks)

Stem: You are the anaesthetist for a 55-year-old man scheduled for open cholecystectomy. He is opioid-naïve with normal renal and hepatic function. The surgeon asks you about postoperative analgesia options using morphine.

---

Examiner: Tell me about the mechanism of action of morphine.

Candidate: Morphine is a natural opioid that acts primarily as a full agonist at the mu (μ) opioid receptor, with lesser activity at kappa (κ) and delta (δ) receptors. The mu receptor is a G protein-coupled receptor linked to inhibitory Gi/Go proteins.

When morphine binds, it causes:

1. Inhibition of adenylyl cyclase, reducing intracellular cAMP
2. Activation of inwardly rectifying potassium channels (GIRK), causing membrane hyperpolarisation
3. Inhibition of voltage-gated calcium channels, reducing calcium influx

At the spinal level, this inhibits release of substance P and glutamate from nociceptive C-fibre terminals. Supraspinally, it activates descending inhibitory pathways from the periaqueductal grey and rostral ventromedial medulla. (3 marks)

---

Examiner: What are the routes by which you could administer morphine postoperatively, and what are the advantages of each?

Candidate:

Intravenous PCA would be my first choice for this surgery:

• Allows patient-controlled titration to individual analgesic needs
• Rapid onset (5-10 minutes to peak effect)
• Typical settings: 1 mg bolus, 5-minute lockout
• Maintains therapeutic plasma levels with less peak-trough variation

Oral morphine (once tolerating oral intake):

• Immediate-release for breakthrough pain (10-20 mg every 4 hours PRN)
• Sustained-release for background analgesia (30-60 mg every 12 hours)
• Lower cost, no IV access required

Subcutaneous (if IV access lost):

• Equivalent bioavailability to IM
• Less painful than IM
• Can be given as continuous infusion

Neuraxial morphine could be considered:

• Epidural (2-4 mg) or intrathecal (0.2-0.3 mg) at time of surgery
• Provides prolonged analgesia (12-24 hours) from single dose
• Spinal morphine particularly effective for abdominal surgery
• However, requires 24-hour monitoring for delayed respiratory depression (4 marks)

---

Examiner: You've started a morphine PCA. The patient is comfortable overnight but becomes increasingly drowsy on postoperative day 2. What might be happening?

Candidate: The differential for increasing drowsiness on day 2 includes:

Opioid-related causes:

1. Cumulative morphine effect—though with normal renal function, significant M6G accumulation is unlikely
2. Relative overdose due to reduced pain (analgesic requirement often decreases as acute inflammation settles)
3. Concurrent sedative medications (benzodiazepines, antiemetics like cyclizine)

Non-opioid causes:

1. Sepsis or infection
2. Metabolic disturbance (hypoglycaemia, hyponatraemia, hypercalcaemia)
3. Hypoxia or hypercapnia
4. Intracranial event (unlikely but consider)
5. Postoperative delirium

My immediate approach would be:

• Assess airway, breathing, circulation
• Check respiratory rate and oxygen saturation
• Review PCA usage (total morphine consumption)
• Check blood glucose, electrolytes, FBC
• Reduce or pause PCA if morphine toxicity suspected
• Naloxone available if respiratory depression present (4 marks)

---

Examiner: The patient's renal function has deteriorated (creatinine risen from 90 to 180 μmol/L). How does this change your management?

Candidate: This is a significant development. The creatinine doubling suggests acute kidney injury (AKIN stage 1-2), which will impair M6G clearance.

Immediate changes:

1. Stop the morphine PCA or reduce dose significantly
2. Switch to a renally-safe opioid:
   • Fentanyl PCA (20-30 mcg bolus, 5-minute lockout)—no active metabolites
   • Hydromorphone PCA (0.2 mg bolus)—inactive metabolites
3. Increase monitoring: Continuous SpO2, hourly sedation scoring
4. Review fluid status: AKI may be hypovolaemic (pre-renal) or related to surgical insult
5. Avoid NSAIDs: Likely already contributing to AKI

Rationale:

• Even mild-moderate renal impairment significantly prolongs M6G half-life
• M6G may continue to accumulate for 24-48 hours even after stopping morphine
• The patient may experience delayed respiratory depression as M6G levels rise
• Reversal with naloxone may be required; consider naloxone infusion if toxicity develops (two-thirds of response dose per hour) (4 marks)

---

Examiner: Can you compare morphine to fentanyl in terms of pharmacokinetics?

Candidate:

The key clinical difference is the active metabolites—fentanyl is much safer in renal impairment. Morphine's histamine release can cause hypotension and pruritus. Fentanyl's high lipophilicity gives faster onset but also faster redistribution and shorter single-dose duration. (3 marks)

---

Examiner: What monitoring would you recommend for a patient receiving intrathecal morphine?

Candidate: Intrathecal morphine requires vigilant monitoring due to the risk of delayed respiratory depression.

ANZCA PS41 recommendations:

• Continuous pulse oximetry for 24 hours post-administration
• Hourly respiratory rate and sedation score for 24 hours
• Supplemental oxygen during sleep or if sedated
• Naloxone readily available at bedside

Timing of risk:

• Peak risk of respiratory depression is 6-12 hours post-administration
• This is due to rostral spread of morphine in CSF (hydrophilic drug moves slowly)
• Risk persists for up to 24 hours

High-risk features requiring enhanced monitoring:

• Age >70 years
• Concurrent systemic opioids or sedatives
• Sleep apnoea
• Pulmonary disease
• Higher intrathecal doses (>0.3 mg)

Monitoring location:

• Should be in a monitored environment (HDU, specialised ward, or recovery area)
• Staff trained in opioid toxicity recognition and management (2 marks)

Total: 20 marks

---

References

1. Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013;65(4):1257-1317. PMID: 24076545

2. Yaksh TL, Wallace MS. Opioids, analgesia, and pain management. In: Brunton LL, ed. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill; 2018.

3. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613-624. PMID: 19567715

4. Hasselström J, Säwe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet. 1993;24(4):344-354. PMID: 8491060

5. Andersen G, Christrup L, Sjøgren P. Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. J Pain Symptom Manage. 2003;25(1):74-91. PMID: 12565191

6. Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther. 1990;47(1):12-19. PMID: 2295214

7. Lotsch J, Geisslinger G. Morphine-6-glucuronide: an analgesic of the future? Clin Pharmacokinet. 2001;40(7):485-499. PMID: 11510626

8. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther. 2004;11(5):354-365. PMID: 15356431

9. Corbett AD, Henderson G, McKnight AT, Paterson SJ. 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol. 2006;147(Suppl 1):S153-S162. PMID: 16402099

10. Stein C. Opioid receptors. Annu Rev Med. 2016;67:433-451. PMID: 26332001

11. Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011;115(6):1363-1381. PMID: 22020140

12. Chahl LA. Opioids - mechanisms of action. Aust Prescr. 1996;19:63-65.

13. Pasternak GW. Molecular biology of opioid analgesia. J Pain Symptom Manage. 2005;29(5 Suppl):S2-S9. PMID: 15907642

14. Kieffer BL, Evans CJ. Opioid receptors: from binding sites to visible molecules in vivo. Neuropharmacology. 2009;56(Suppl 1):205-212. PMID: 18718480

15. Matthes HW, Maldonado R, Simonin F, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 1996;383(6603):819-823. PMID: 8893006

16. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11(2 Suppl):S133-S153. PMID: 18443637

17. Mather LE, Smith MT. Clinical pharmacokinetics of morphine. Clin Pharmacokinet. 1983;8(5):422-446. PMID: 6226471

18. Christrup LL. Morphine metabolites. Acta Anaesthesiol Scand. 1997;41(1 Pt 2):116-122. PMID: 9061094

19. Thompson PI, Joel SP, John L, Wedzicha JA, Maclean M, Slevin ML. Respiratory depression following morphine and morphine-6-glucuronide in normal subjects. Br J Clin Pharmacol. 1995;40(2):145-152. PMID: 8562297

20. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology. 2010;112(1):226-238. PMID: 20010421

21. Pattinson KT. Opioids and the control of respiration. Br J Anaesth. 2008;100(6):747-758. PMID: 18456641

22. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94(7):961-972. PMID: 10707430

23. Williams JT, Ingram SL, Henderson G, et al. Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev. 2013;65(1):223-254. PMID: 23321159

24. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol. 2008;154(2):384-396. PMID: 18414400

25. Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;16(5):405-416. PMID: 18837637

26. Kuo A, Wyse BD, Meutermans W, Smith MT. In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile. Br J Pharmacol. 2015;172(2):532-548. PMID: 24641546

27. Murphy PB, Bechmann S, Barrett MJ. Morphine. In: StatPearls. StatPearls Publishing; 2024. PMID: 30252288

28. Mikus G, Weiss J. Influence of CYP2D6 genetics on opioid kinetics, metabolism and response. Curr Pharmacogenomics. 2005;3(1):43-52.

29. Dean L. Codeine therapy and CYP2D6 genotype. In: Medical Genetics Summaries. NCBI; 2012. PMID: 28520350

30. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007;7(4):257-265. PMID: 16819548

31. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain. 2002;18(4 Suppl):S3-S13. PMID: 12479250

32. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer. 1999;86(9):1856-1866. PMID: 10547562